Pantalone KM, et al. - The objective of this study was to examine the efficacy and safety of dulaglutide 1.5 mg combined with insulin, categorised by subgroups of baseline HbA1c (≤9% and >9%), age (<65 and ≥65 years), and duration of diabetes (<10 and ≥10 years) at 6 months in patients with type 2 diabetes (T2D). Based on the yielded data, it was revealed that dulaglutide 1.5 mg combined with basal or prandial insulin was efficacious for patients with T2D regardless of age, duration of diabetes, and baseline HbA1c.